Revenue + 35%, substantial improvement in earnings

Kleinostheim, July 21, 2005 – curasan AG (WKN 549 453) today announced its financial results for the second quarter ended June 30, 2005. In the second quarter, the company generated revenue of EUR 2.3 million (Q2 2004: EUR 1.7 million) and a loss before interest and taxes of EUR 519 thousand (Q2 2004: loss of EUR 848 thousand).The net loss for the period improved to EUR 311 thousand (Q2 2004: loss of EUR 657 thousand).

Revenue was 35% higher than in the same period a year ago. At 38%, year-on-year EBIT growth was even more pronounced.

The double-digit increase in revenue was attributable mainly to the positive development of the company's international business – particularly with the new curasan-product curavisc® against joint arthrosis – as well as higher sales volumes within the area of bone regeneration and from the haemostatic product stypro ® .

The company also continued to apply a stringent programme of cost management. As a result of savings within this area, earnings improved substantially in the second quarter.

In addition, the successful placement of 250,000 shares issued as part of a capital increase in the second quarter raised awareness among investors and allowed curasan AG to regain a more prominent position within the financial markets. The company's management sees the first-half results as confirmation of curasan's turnaround forecast for 2006.

The full quarterly report will be published on August 11 and can be accessed via the company's website.

Top of page Print page